Shilpa Medicare Limited — Investor Meet, 10-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Shilpa Medicare delivered a stellar Q3 FY26, hitting record revenue of ₹411 Cr (+28% YoY) and EBITDA of ₹115 Cr (+41% YoY), with margins at 28%. The 9M PAT doubled last year's full-year profit, reflecting strong acceleration. Formulation sales surged 50% YoY, boosted by the successful NorUDCA launch (exceeded expectations, firm orders) and 100% growth in EU. Key investments are complete; focus shifts to execution for maximum ROCE. Biologics (Aflibercept, new biosimilars, 1st ADC) are progressing globally, with partnerships expected FY27. A ₹40 Cr peptide manufacturing capex for GLP-1 products is underway. Management signals a confident outlook, anticipating continued growth from Formulation and Biologics.